The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia

Blood

Volumn 118, Issue 24, 2011, Pages 6353-6361

  Morabito, Fortunato ^a   De Filippi, Rosaria ^b,c   Laurenti, Luca ^d   Zirlik, Katja ^e   Recchia, Anna Grazia ^a   Gentile, Massimo ^a   Morelli, Emanuela ^b   Vigna, Ernesto ^a   Gigliotti, Vincenzo ^a   Calemma, Rosa ^b   Amoroso, Barbara ^f   Neri, Antonino ^g   Cutrona, Giovanna ^h   Ferrarini, Manlio ^h   Molica, Stefano ⁱ   Del Poeta, Giovanni ^j   Tripodo, Claudio ^k   Pinto, Antonio ^b  

^a Azienda Ospedaliera Annunziata   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF FREIBURG   (Germany)

^f Binding Site Group Ltd   (United Kingdom)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ PUGLIESE CIACCIO HOSPITAL   (Italy)

^j UNIVERSITY OF ROME TOR VERGATA   (Italy)

^k UNIVERSITY OF PALERMO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS;

EID: 83455210395     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-345587     Document Type: Article

References (36)

1. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437-1444. (Pubitemid 34925779)
2. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47(4):673-680. (Pubitemid 32275810)
3. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215-224.
4. Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA. Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci. 2008;29(4):170-174.
5. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3(6):1684-1690.
6. Gordon J, Howlett AR, Smith JL. Free light chain synthesis by neoplastic cells in chronic lymphocytic leukaemia and non-Hodgkin's lymphoma. Immunology. 1978;34(3):397-404. (Pubitemid 8292916)
7. Pratt G, Harding S, Holder R, et al. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological sub-groups in patients with chronic lymphocytic leukaemia. Br J Haematol. 2009;144(2):217-222.
8. Yegin ZA, Ozkurt ZN, Yagci M. Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemia. Eur J Haematol. 2010; 84(5):406-411.
9. Zenz T, Frohling S, Mertens D, Dohner H, Stilgenbauer S. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010;23(1):71-84.
10. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12): 5446-5456.
11. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8(10):1640-1645. (Pubitemid 24323778)
12. Cutrona G, Colombo M, Matis S, et al. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. Haematologica. 2008;93(3):413-422. (Pubitemid 351398643)
13. O'Brien S, Keating MJ. Chronic lymphoid leukemias. In: De Vita T, Hellman J, Rosenberg S, eds. Cancer Principle & Practice of Oncology. Vol 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:2133-2142.
14. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98(9):2633-2639.
15. Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood. 2006;108(3):853-861. (Pubitemid 44154617)
16. Morabito F, Cutrona G, Gentile M, et al. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol. 2009;146(1):44-53.
17. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102(8):1515-1525. (Pubitemid 28492218)
18. Fabris S, Mosca L, Todoerti K, et al. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2008;47(9):781-793.
19. Tripodo C, Gri G, Piccaluga PP, et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177(2):792-802.
20. Altman D. Practical Statistics for Medical Research. London, United Kingdom: Chapman Hall; 1991.
21. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4): 361-387. (Pubitemid 26072233)
22. Kostareli E, Sutton LA, Hadzidimitriou A, et al. Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution. Leukemia. 2010;24(7):1317-1324.
23. Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia. 2009; 23(12):2233-2241.
24. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia. 1997;11(4):572-580. (Pubitemid 27173945)
25. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010;115(13):2619-2629.
26. Gottenberg JE, Aucouturier F, Goetz J, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis. 2007;66(1):23-27. (Pubitemid 46044856)
27. Tsai HT, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 2009; 114(24):4928-4932.
28. Lanasa MC, Allgood SD, Volkheimer AD, et al. Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. Leukemia. 2010;24(1):133-140.
29. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28(5):773-779.
30. Oltz EM. Regulation of antigen receptor gene assembly in lymphocytes. Immunol Res. 2001;23(2-3):121-133. (Pubitemid 32575354)
31. Rice JS, Newman J, Wang C, Michael DJ, Diamond B. Receptor editing in peripheral B cell tolerance. Proc Natl Acad Sci U S A. 2005;102(5): 1608-1613. (Pubitemid 40209215)
32. Labrie JE 3rd, Sah AP, Allman DM, Cancro MP, Gerstein RM. Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B cell generation in aged mice. J Exp Med. 2004;200(4):411-423. (Pubitemid 39121899)
33. Saborit-Villarroya I, Vaisitti T, Rossi D, et al. E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. Leukemia. 2011; 25(3):479-488.
34. Dispenzieri A, Katzmann JA, Kyle RA, Larson D, Rajkumar SV. Non-clonal serum immunoglobulin free light chains (FLC) as markers of overall survival. Hematol Rep. 2010;2(s2):12.
35. Rijnierse A, Redegeld FA, Blokhuis BR, et al. Ig-free light chains play a crucial role in murine mast cell-dependent colitis and are associated with human inflammatory bowel diseases. J Immunol. 2010;185(1):653-659.
36. Tripodo C, Sangaletti S, Piccaluga PP, et al. The bone marrow stroma in hematological neoplasmas- a guilty bystander. Nat Rev Clin Oncol. 2011;8(8):456-466.